MiR-486-3p Inhibits the Proliferation, Migration and Invasion of Retinoblastoma Cells by Targeting ECM1

Hongwei Yang¹*, Yonggang Huang²*, Jian He³, Guangrui Chai¹, Yu Di¹, Aiyuan Wang¹, Dongmei Gui¹

¹Department of Ophthalmology, Shengjing Hospital of China Medical University

²School of Mechanical Engineering and Automation, Northeastern University

³Department of Ophthalmology, Jinzhou Central Hospital

*These authors contributed equally to this work.

Corresponding author: Hongwei Yang, Department of Ophthalmology, Shengjing Hospital of China Medical University, No.36, Sanhao Street, Shenyang, Liaoning, 110004, China, E-mail: yhw_yahowe@163.com, Tel: 86-024-96615

Running title: Role of miR-486-3p in retinoblastoma
Abstract

It has reported that miR-486-3p expression is decreased in retinoblastoma (RB) tumor tissues, however, its function in RB has been less reported. This study aimed to explore the regulatory effects of miR-486-3p on RB cells. The expression of miR-486-3p in RB tissues and cells was detected by quantitative real-time (qRT)-PCR. Cell viability, proliferation, apoptosis, migration and invasion ability were determined by cell counting kit-8 kit, clone formation assay, flow cytometry, scratch assay and transwell, respectively. Targetscan 7.2 and dual-luciferase reporter were used to verify target genes for miR-486-3p. The expressions of apoptosis-related proteins and ECM1 were detected by Western blot. The miR-486-3p expression was decreased in RB tissues and cells. In RB cells, overexpression of miR-486-3p inhibited cell proliferation, migration and invasion, while promoted apoptosis. Moreover, overexpression of miR-486-3p decreased Bcl-2 expression, while increased the expressions of Bax and C caspase-3. ECM1 was the target gene of miR-486-3p, and miR-486-3p inhibited the expression of ECM1. Furthermore, ECM1 partially reversed the inhibitory effect of miR-486-3p on the proliferation, migration and invasion of RB cells. MiR-486-3p inhibited the proliferation, migration and invasion of RB by down-regulating ECM1.

Keywords: miR-486-3p; Retinoblastoma; Proliferation; Migration; ECM1
Introduction

Retinoblastoma (RB) is a common intraocular tumor in infants and young children, which seriously endangers the vision and life of children (1, 2). Early and timely treatment of RB patients can achieve better survival rate and retention of visual function (3, 4), while the tumor will grow and spread rapidly within the eyeball, invade the vitreous body and subretinal space, spread to the skull along the optic nerve, leading to the death of the patient, without timely diagnosis or treatment (5-7). At present, the common treatment methods for RB are transpupillary thermal therapy, cryotherapy, chemotherapy, and ophthalmectomy, orbital exenteration and gene therapy (8, 9). Gene therapy is the treatment of a disease by manipulating a therapeutic gene or disease-related gene as a therapeutic target, which has a good prospect in the application of multiple tumor therapies (10, 11). Thus, it is important to explore the biological and molecular mechanisms of RB in order to identify new diagnostic criteria and therapeutic targets.

MicroRNAs (miRNAs) are non-coding single-stranded RNAs that inhibit or degrade the mRNA by binging with the target mRNA 3'-untranslation region (3'-UTR), and regulate the target genes expression (12-14). Previous studies have demonstrated that miRNA expression may be specific to certain types of cancer and tumor-derived miRNAs may be stably detected in the plasma or serum (15, 16). In recent years, it has been reported that plasma miR-320, miR-let-7e and miR-21 was act as novel potential biomarkers for the detection of retinoblastoma (17). In addition, studies have found that many miRNAs are abnormally expressed in RB, such as miR-192,
miR-34a and miR-376a (18-21). miR-125b promoted tumor growth and suppresses apoptosis by targeting DRAM2 in retinoblastoma (22). miRNA-188-5p promoted epithelial-mesenchymal transition via targeting DNA binding 4 through Wnt/β-catenin Signaling in retinoblastoma (23). These studies indicate that abnormal miRNA abnormally expression may have some influence on the development of RB. Therefore, the discovery of abnormally expressed miRNAs and their target genes in RB may provide a new idea for the research and treatment of the molecular mechanism of RB.

Studies have shown that miR-486-3p is abnormally expressed in a variety of cancer cells, such as oral cancer, cervical cancer and oral tongue squamous cell carcinoma (24-26). The down-regulation of miR-486-3p is considered as one of the causes for metastasis of cervical cancer (25). Venkatesan et al. found that miR-486-3p expression was decreased in the RB tumor tissues (27), however, the role of miR-486-3p in RB is unclear. In the present study, clone formation assay, flow cytometry, transwell chamber and other experimental methods were used to investigate the effect of overexpression of miR-486-3p on the proliferation, apoptosis and invasion ability of RB, in order to provide new ideas for clinical treatment of RB.

**Materials and Methods**

**Reagent**

RPMI-1640 medium (31870082; Gibco, USA); 10% fetal bovine serum (FBS, 16140071; Gibco, USA); 100 U/ml penicillin (10378016; Gibco, USA); 100 μg /mL streptomycin (10378016; Gibco, USA); Lipofectamine 2000 Transfection Reagent
(11668030; Invitrogen, USA); wright's-giemsa's staining solution (G5225; GBCBIO technologies Inc., China); paraformaldehyde (P0099-500ml; Beyotime, China); crystal violet (C0121; Beyotime, China); Trizol reagent (15596026; Invitrogen, USA); SYBR miRNA detection assays (Takara, China); RIPA buffer (P0013K; Beyotime, China); PVDF membrane (Merck, Germany); Cell counting kit-8 kit (CCK-8, C0037; Beyotime, China); Annexin V-FITC Apoptosis Detection kit (APOAF; Sigma-Aldrich, USA); PrimeScript RT Master Mix kit (RR036A; Takara, China); BCA protein assay kit (23225; Pierce, Germany).

**Clinical samples and cell culture**

Human tissue samples (including RB tumor tissues and normal retinal tissues) of 45 patients with RB who were underwent eye enucleation in Shengjing Hospital of China Medical University were collected. All patients were not treated with radiotherapy or chemotherapy before operation, the postoperative pathological sections were diagnosed as RB. The samples were frozen and stored in liquid nitrogen, the tissues used for pathological examination were fixed by 4% paraformaldehyde. The experimental procedure was approved by Ethics Committee of Shengjing Hospital of China Medical University, and the written informed consent of each patient was obtained.

Human retinal pigment epithelial cells (ARPE-19) and RB cell lines (Y79, SO-RB50, WERI-Rb-1) were both purchased from the Typical Cell Culture Collection Committee of the Chinese Academy of Sciences Library (http://www.cellbank.org.cn/search.asp?a=1). All cells were cultured in RPMI-1640
medium containing 10% FBS, 100 U/ml penicillin, 100 μg/mL streptomycin at 37°C with 5% CO₂.

**Transfection**

Transfection of miRNA: Y79 and SO-RB50 were transfected with miR-486-3p mimic (mimic group) or miR-486-3p mimic control (mimic control group) by Lipofectamine 2000 Transfection Reagent, according to the manufacturer’s instructions. The single cell suspension at a density of 5×10⁴ cells/ml was prepared and seeded into the 96-well plate. The miRNA was mixed with OPTIM-MEM 1, and then the Lipofectamine 2000 reagent and OPTIM-MEM 1 were added and incubated for 20 min. Then, the mixture was incubated at 37°C with 5% CO₂ for 48 h. The untreated cells were set up as control group (blank group).

Transfection of vector: The expression vector with wild type/mutant ECM1-3’-UTR sequences was designed and synthesized by Shanghai GenePharma Co., Ltd (China). Y79 and SO-RB50 were co-transfected with miR-486-3p mimic and ECM1-WT or ECM1-MUT. The untreated cells were set up as control group (blank group). The experiment was divided into 4 groups: blank-ECM1-WT group, mimic-ECM1-WT group, blank- ECM1-MUT group, and mimic- ECM1-MUT group. For another transfection experiments, Y79 and SO-RB50 were co-transfected with miR-486-3p mimic control or miR-486-3p mimic and ECM1-WT (ECM1) or empty vector (negative control, NC). The experiment was divided into 4 groups: Mimic control+NC group, Mimic control +ECM1 group, Mimic+NC group, and Mimic+ECM1 group.
Cell viability assay

Cell counting kit-8 kit was performed to determine the cell viability of Y79 and SO-RB50. The cell density was adjusted to $5 \times 10^5$ cells/ml and inoculated in a 96-well plate and cultured for 24, 48, 72h, then the CCK-8 solution was added and again cultured for 2h. Optical density (OD) of each well was measured at the wavelength of 450 nm by a microplate (Model 680, Bio-Rad, USA).

Clone formation assay

Cells were re-suspended in RPMI-1640 and seeded into a 35 mm culture dish with 500 cells per plate, and cultured at 37°C in a 5% CO$_2$ cell culture incubator. After 14 days, the cells were fixed with 4% poly-methanol for 20 min, then stained with wright's-giemsa's staining solution for 10 min. After natural air drying, the images were observed and counted under the inverted phase contrast microscope (CK40, Olympus, Japan).

Cell apoptosis

The Annexin V-FITC Apoptosis Detection kit was performed to determine cell apoptosis. Cells at the density with $1 \times 10^6$ cells/ml were resuspended in binding buffer. Then, the mixture was mixed with Annexin V-FITC and incubated in dark environment for 10 min. The propidium iodide (PI) was added, and then incubated in dark environment for 15 min. Cell apoptosis was analyzed by flow cytometry (BD FACSCalibur, BD Biosciences, USA).

Scratch assay

Cells were seeded into a 24-well plate at a density of $5 \times 10^5$ cells/ml, and a
straight wound was created by a sterile pipette tip. At 0 and 48 h after the wounding, the cells were imaged by inverted phase-contrast microscope (Eclipse TS100, Nikon, Japan) and the cell migration was analyzed by NIS-Element Basic Research v3.2 software (Nikon, Japan).

**Transwell**

Transwells chambers (8 μm pores, Corning Company, USA) pre-coated with Matrigel were placed into a 24-well plate, and the cells were seeded on the upper chambers at a density of 2×10^5 cells/well. The serum-free medium was added to the upper chamber, the RPMI-1640 medium with 10% FBS was added to the lower chamber. After 48 h, the excess culture fluid was removed and the migrated cells were fixed with 4% paraformaldehyde for 5 min, and then stained with 0.1% crystal violet for 5 min. The image was observed under an inverted microscope (TS100, Nikon, Japan).

**miRNA target prediction and dual-luciferase reporter assay**

The Targetscan 7.2 (http://www.targetscan.org/) was used to predict the potential target of miR-486-3p. The miR-486-3p mimic and ECM1-WT or ECM1-MUT were co-transfected into Y79 and SO-RB50 by Lipofectamine 2000 Transfection Reagent, respectively. The untreated cells were set up as control group (blank group). The luciferase activities were measured using the Dual-luciferase Reporter Assay kit (Promega, USA).

**Quantitative real-time polymerase chain reaction (qRT-PCR)**

Total RNA was isolated from cells by Trizol reagent. RNA purity and
concentration were determined by Nano Drop 2000 (Thermo Fisher Scientific, USA). The total RNA (2 μg) was reverse transcribed to cDNA by PrimeScript RT Master Mix kit. Then, SYBR miRNA detection assays and Opticon real-time PCR Detection System (ABI 7500, Life technology, USA) were used for quantitative analysis. The response procedure: 94℃ for 5 min, (94℃ for 30 s, 58℃ for 30 s, 72℃ for 30 s) ×35 cycles, and 72℃ for 5 min. The expression level was calculated using $2^{-\Delta\Delta CT}$ method. U6 was used as internal reference gene, and the primers for qRT-PCR used in this study were shown in Table 2.

**Western blot**

Total protein was lysed with RIPA buffer and then was quantified with BCA protein assay kit. The protein (20 μg) was separated by 10% SDS-PAGE, and transferred to PVDF membrane. The membrane was blocked with 5% skim milk solution for 1 h, and then incubated with primary antibodies overnight at 4℃: anti-Bcl-2 (ab59348, 1:1000, Abcam), anti-Bax (ab32503, 1:1000, Abcam), anti-Cleaved Caspase-3 (C caspase-3, #9661, 1:1000, CST), anti-GAPDH (ab8245, 1:2000, Abcam), anti- Extracellular matrix protein 1 (ECM1, ab126629, 1:1000, Abcam). Next, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 2 h: goat anti-rabbit IgG H&L (HRP) (ab205718, 1:2000, Abcam), goat anti-mouse IgG H&L (HRP) (ab205719, 1:2000, Abcam). GAPDH was used as a control. The protein band was analyzed by Pierce Western Blotting ECL substrate kit (Thermo Fisher Scientific, USA) and BandScan 5.0 system (Bio-Rad, Hercules, USA).
Statistical analysis

Experiments were repeated at least 3 times. SPSS 20.0 system (SPSS Inc., USA) was used for statistical analysis. All experimental data was presented as the mean ± standard deviation (SD). Comparisons between groups were analyzed with student’s tests or one-way ANOVA. P <0.05 was considered to be statistically significant.

Results

miR-486-3p was down-regulated in RB tissues and cell lines

The expression of miR-486-3p in tissues and cell lines (ARPE-19, Y79, SO-RB50, WERI-Rb-1) was measured by qRT-PCR. The miR-486-3p level was lower in RB tumor tissues (RB group) than that in normal retinal tissues (normal group, Fig 1A, P<0.05). Moreover, compared with ARPE-19, the miR-486-3p level was lowly expressed in Y79, SO-RB50 and WERI-Rb-1 (Fig 1B, P<0.05). Compared with normal tissues and cells, the expression of miR-486-3p was significantly decreased in RB tissues and cells, which may indicate that miR-486-3p was involved in the occurrence and development of RB.

miR-486-3p was up-regulated by miR-486-3p mimic

Our previous experiments showed that miR-486-3p level was lower in Y79 and SO-RB50; therefore, Y79 and SO-RB50 were selected to investigate the effect of miR-486-3p on RB. Y79 and SO-RB50 were transfected with miR-486-3p mimic control (mimic control group) and miR-486-3p mimic (mimic group), respectively, and a blank group was set. The transfection of overexpressed miR-486-3p was detected by qRT-PCR, and miR-486-3p level was highly expressed in mimic group
(including Y79 and SO-RB50) (Fig 2A, \( P<0.05 \)), miR-486-3p mimic up-regulated miR-486-3p expression.

**miR-486-3p mimic inhibited cell proliferation**

Cell viability and the ability of cell cloning were detected by CCK-8 and clone formation assay. As shown in Fig 2BC, in Y79 and SO-RB50 cell lines, the cell viability was lower in mimic group than that in blank group and mimic control group \( (P<0.05) \). Clone formation assay demonstrated that the clones in Y79-mimic and SO-RB50-mimic groups were lower than those in corresponding blank and mimic control groups (Fig 2E, \( P<0.05 \)). The cell viability and the ability of cell cloning were inhibited by miR-486-3p.

**miR-486-3p mimic promoted apoptosis**

For the apoptosis of Y79 and SO-RB50, the apoptosis rate and the expressions of related apoptotic proteins were detected by flow cytometry and Western blot. In Y79 cell line, the apoptosis rate was higher in mimic group than that in blank and mimic control groups (Fig 2F, \( P<0.05 \)). Moreover, compared with blank and mimic control groups, in mimic group, Bcl-2 expression was down-regulated, while the Bax and C caspase-3 expressions were up-regulated (Fig 3B, \( P<0.05 \)). In addition, in SO-RB50 cell line, compared with blank and mimic control groups, the apoptosis rate (Fig 2F) and the Bax and C caspase-3 expressions (Fig 3D) in mimic group were up-regulated, and the Bcl-2 expression (Fig 3D) was down-regulated \( (P<0.05) \). We found that miR-486-3p mimic promoted apoptosis.

**miR-486-3p mimic inhibited cell migration and invasion**
The cell migration and invasion were detected by scratch and transwell. In Y79 and SO-RB50 cell line, compared with blank and mimic control groups, the cell migration (Fig 4B) and invasion (Fig 4C) in mimic group were down-regulated ($P<0.05$), suggesting that miR-486-3p inhibited cell migration and invasion.

**ECM1 was a target gene of miR-486-3p in RB cells**

To study the mechanism of miR-486-3p in RB cells, the Targetscan7.2 was performed to predict the target gene and the potential binding sites of miR-486-3p. As shown in Fig 5A, the 3’UTR of ECM1 contained an area that matched to the miR-486-3p sequence. Then, Y79 and SO-RB50 were co-transfected with miR-486-3p mimic and ECM1-WT or ECM1-MUT to confirm whether miR-486-3p can bind to ECM1, and the dual-luciferase reporter was used to determine the luciferase activity. In Y79 and SO-RB50 cell lines, it was found that the luciferase activity in mimic-ECM1-WT group was reduced, while no reduction was observed in that of mimic-ECM1-MUT group (Fig 5BC, $P<0.05$), ECM1 was a target gene of miR-486-3p.

**miR-486-3p inhibited ECM1 expression**

In this study, the ECM1 vectors (containing 3’UTR) were transfected into miR-486-3p-expressing RB cells, and a control group was set up. The experimental design was divided into 4 groups: mimic control+NC group, mimic control +ECM1 group, mimic+NC group and mimic+ECM1 group, and western blot was performed to confirm ECM1 expression in RB cells. We found that in Y79 and SO-RB50 cell lines, compared with mimic control + NC group, ECM1 protein level was highly expressed.
in mimic control +ECM1 group, and lowly expressed in mimic+NC group (Fig 6C, $P<0.05$). At the same time, ECM1 protein level in mimic+ ECM1 group was lower than that in mimic control +ECM1 group but was higher than that in mimic+NC group (Fig 6C, $P<0.05$). ECM1 level was inhibited by miR-486-3p mimic in RB cells, and ECM1 vectors restored the ECM1 expression.

**ECM1 reversed the effect of miR-486-3p on RB cells**

The cell proliferation, apoptosis, migration and invasion of transformed Y79 and SO-RB50 were determined by CCK-8, clone formation assay, flow cytometry, scratch and transwell. Compared with mimic control + NC group, cell viability (Fig 6D), clones (Fig 6H), migration (Fig 7B) and invasion (Fig 7C) were up-regulated in mimic control + ECM1 groups and down-regulated in mimic+ NC group ($P<0.05$). The cell viability (Fig 6D), clones (Fig 6H), migration (Fig 7B) and invasion (Fig 7C) in mimic+ ECM1 group were higher than those in mimic +NC group and lower than those in mimic control + ECM1 group ($P<0.05$). In addition, the apoptosis in mimic+NC group was up-regulated as compared to mimic control + NC group, and the apoptosis in mimic + ECM1 group was higher than that in mimic control + ECM1 group but was lower than that in mimic + NC group (Fig 6F, $P<0.05$). ECM1 could promote cell proliferation, migration and invasion, and inhibit apoptosis, as well as reverse the effect of miR-486-3p on RB cells. The miR-486-3p may play a role in RB by regulating ECM1 expression.

**Discussion**

In this study, we found that miR-486-3p level was down-regulated in RB tissues
and cells, suggesting that miR-486-3p was involved in the development of RB. Nalini Venkatesan et al. (27) also found that the miR-486-3-p expression was down-regulated in RB samples. Then, in vitro experiments were conducted, and demonstrated that miR-486-3p overexpression inhibited the proliferation, migration and invasion, and promoted the apoptosis of RB. At the same time, the downstream target gene of miR-486-3p was analyzed and verified, and found ECM1 was the target gene of miR-486-3p and ECM1 expression was suppressed by overexpressed miR-486-3p. Finally, the role of miR-486-3p combined with target gene in RB cells was observed, and found that overexpression of ECM1 partially reversed the effect of miR-486-3p on RB cells. These results support the conclusion that miR-486-3p plays a crucial role in RB progression.

Continuous proliferation of tumor cells is one of the basic biological characteristics of tumor progression (28). In normal conditions, the cell proliferation and apoptosis are in a dynamic equilibrium state, and abnormal cell growth or death can lead to tumor or excessive tumor cells (29). In addition, tumor metastasis is an important cause for poor prognosis of cancer patients, and important biological characteristics of tumor metastasis are cell migration and invasion (30). Tumor cells can enter the microcirculation through the microvessels and lymphatic vessels, and invade into the surrounding tissues, resulting in tumor metastasis (31, 32). In this study, the role of miR-486-3p on the proliferation, migration and invasion of RB cells was investigated, and the result showed that overexpression of miR-486-3p could inhibit the cell proliferation, migration and invasion of RB cells. The results revealed
that miR-486-3p may play an anticancer role in RB. In other studies, mir-486-3p has been reported to have an inhibitory effect on cancer, such as glioblastoma (33), oral cancer (24) and cervical cancer (25).

In addition, the occurrence of cancer is closely related to the abnormal apoptosis regulation mechanics, which may lead to the increase of the number of tumor cells (34, 35). Meanwhile, the occurrence of apoptosis is a complex process, which is strictly regulated by many genes, including pro-apoptotic genes and apoptotic suppressor genes (36). Bax is the most widely studied pro-apoptotic protein, which can form hetero dimer with Bcl-2 (an anti-apoptotic protein), thus acting as apoptotic activator (37). Caspase-3 belongs to the apoptotic effector gene, and the activated caspase-3 will trigger a cascade reaction, leading to irreversible apoptosis (38). In this study, it was found that miR-486-3p promoted the apoptosis of RB cells by down-regulating the Bcl-2 level, increasing the Bax level and activating caspase-3, and thereby inhibiting the malignant progression of RB.

MiRNAs participate in a variety of physiological and pathological processes by regulating their multiple target genes (39). It has been reported that miR-486-3p plays a critical role in proliferation and metastasis by repressing various oncogenes, including DDR1 (24) and BMP2 (40). To further clarify the mechanism of miR-486-3p in RB, the target gene of miR-486-3p was identified. In this paper, ECM1 was identified as the functional target of miR-486-3p in RB cells. ECM1 was as a “biological glue” binding to components of the dermal-epidermal junction in the framework of normal skin (41). ECM1 was first found in osteoblasts stromal cells,
and high ECM1 levels were subsequently detected in bladder cancer (42), thyroid cancer (43) and other malignant tumors (44). Hao Chen et al. (45) showed that ECM1 was highly expressed in hepatocellular carcinoma specimens, and could promote the migration and invasion of HCC cells. In cervical cancer, miR-486-3p inhibited cell proliferation by targeting ECM1 (25). We discovered that the overexpression of miR-486-3p significantly inhibited the ECM1 expression in RB cells, ECM1 could partially reverse the effects of miR-486-3p on RB cells, and promote cell proliferation, while inhibit apoptosis. The above results indicated that miR-486-3p may play a tumor suppressive role in RB through inhibiting the ECM1 expression.

In conclusion, miR-486-3p expression was decreased in RB tissues and participated in the development of RB. Moreover, miR-486-3p inhibited the cell proliferation, migration, and invasion, and promoted apoptosis by inhibiting ECM1 expression, thus inhibiting the malignant progression of RB. This study suggests that miR-486-3p may be a potential therapeutic target for clinical treatment of RB.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Funding information**

This work was supported by the National Natural Science Foundation of China [Grant Number 81372878].

**Author contribution statement**

Substantial contributions to conception and design: HY, YH

Data acquisition, data analysis and interpretation: JH, GC, YD
Drafting the article or critically revising it for important intellectual content: AW, DG, YH

Final approval of the version to be published: All authors

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved: HY

References

1. Benavente CA, Dyer MA. Genetics and epigenetics of human retinoblastoma. Annual review of pathology. 2015;10:547-62.
2. Yang J, Dang Y, Zhu Y, Zhang C. Diffuse anterior retinoblastoma: current concepts. OncoTargets and therapy. 2015;8:1815-21.
3. Zhang L, Gao T, Shen Y. Quality of life in children with retinoblastoma after enucleation in China. Pediatric blood & cancer. 2018;65(7):e27024.
4. Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89(10):2117-21.
5. Hu H, Zhang W, Wang Y, Huang D, Shi J, Li B, et al. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC ophthalmology. 2018;18(1):107.
6. Kunkele A, Wilm J, Holdt M, Lohmann D, Bornfeld N, Eggert A, et al. Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. The British journal of ophthalmology. 2015;99(7):949-53.
7. Al-Nawaiseh I, Ghanem AQ, Yousef YA. Familial Retinoblastoma: Raised Awareness Improves Early Diagnosis and Outcome. Journal of ophthalmology. 2017;2017:5053961.
8. Ghassemi F, Khodabande A. Risk definition and management strategies in retinoblastoma: current perspectives. Clinical ophthalmology (Auckland, NZ).
2015;9:985-94.

9. Kim JY, Park Y. Treatment of Retinoblastoma: The Role of External Beam Radiotherapy. Yonsei medical journal. 2015;56(6):1478-91.

10. Philiponnet A, Grange JD, Baggetto LG. [Application of gene therapy to oncologic ophthalmology]. Journal francaises d'ophtalmologie. 2014;37(2):155-65.

11. Okura H, Smith CA, Rutka JT. Gene therapy for malignant glioma. Molecular and cellular therapies. 2014;2:21.

12. Liu K, Huang J, Xie M, Yu Y, Zhu S, Kang R, et al. MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy. 2014;10(3):442-52.

13. Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC, et al. miRNA nanotherapeutics for cancer. Drug discovery today. 2017;22(2):424-32.

14. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518(7537):107-10.

15. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(8):2334-40.

16. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British journal of haematology. 2008;141(5):672-5.

17. Liu SS, Wang YS, Sun YF, Miao LX, Wang J, Li YS, et al. Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. Biomedical reports. 2014;2(3):424-8.

18. Castro-Magdonel BE, Orjuela M, Camacho J, Garcia-Chequer AJ, Cabrera-Munoz L, Sadowinski-Pine S, et al. miRNOME landscape analysis reveals a 30 miRNA core in retinoblastoma. BMC cancer. 2017;17(1):458.

19. Feng S, Cong S, Zhang X, Bao X, Wang W, Li H, et al. MicroRNA-192 targeting
retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic acids research. 2011;39(15):6669-78.

20. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Investigative ophthalmology & visual science. 2009;50(10):4542-51.

21. Zhang Y, Wu JH, Han F, Huang JM, Shi SY, Gu RD, et al. Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a. Neoplasma. 2013;60(3):247-53.

22. Bai S, Tian B, Li A, Yao Q, Zhang G, Li F. MicroRNA-125b promotes tumor growth and suppresses apoptosis by targeting DRAM2 in retinoblastoma. Eye (London, England). 2016;30(12):1630-8.

23. Yang M, Li Y, Wei W. MicroRNA-188-5p Promotes Epithelial-Mesenchymal Transition by Targeting ID4 Through Wnt/betacatenin Signaling in Retinoblastoma. OncoTargets and therapy. 2019;12:10251-62.

24. Chou ST, Peng HY, Mo KC, Hsu YM, Wu GH, Hsiao JR, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1. Journal of experimental & clinical cancer research : CR. 2019;38(1):281.

25. Ye H, Yu X, Xia J, Tang X, Tang L, Chen F. MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;80:109-14.

26. Chen Z, Yu T, Cabay RJ, Jin Y, Mahjabeen I, Luan X, et al. miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma. Biomarkers in cancer. 2017;9:1-8.

27. Venkatesan N, Deepa PR, Khetan V, Krishnakumar S. Computational and in vitro Investigation of miRNA-Gene Regulations in Retinoblastoma Pathogenesis: miRNA Mimics Strategy. Bioinformatics and biology insights. 2015;9:89-101.

28. Zhang H, Zhong J, Bian Z, Fang X, Peng Y, Hu Y. Long non-coding RNA CCAT1 promotes human retinoblastoma SO-RB50 and Y79 cells through negative regulation of miR-218-5p. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;87:683-91.
29. Bortner CD, Cidlowski JA. Ion channels and apoptosis in cancer. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2014;369(1638):20130104.

30. Khosravi A, Shahrabi S, Shahjahani M, Saki N. The bone marrow metastasis niche in retinoblastoma. Cellular oncology (Dordrecht). 2015;38(4):253-63.

31. Riggi N, Aguet M, Stamenkovic I. Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment. Annual review of pathology. 2018;13:117-40.

32. Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends in cell biology. 2014;24(3):153-60.

33. Wu H, Li X, Zhang T, Zhang G, Chen J, Chen L, et al. Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT. Neuromolecular medicine. 2020.

34. Singh L, Pushker N, Saini N, Sen S, Sharma A, Bakhshi S, et al. Expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. Clinical & experimental ophthalmology. 2015;43(3):259-67.

35. Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget. 2015;6(20):17873-90.

36. Natalino RJ, Antoneli CB, Ribeiro KC, Campos AH, Soares FA. Immunohistochemistry of apoptosis-related proteins in retinoblastoma. Pathology, research and practice. 2016;212(12):1144-50.

37. Wang LL, Hu HF, Feng YQ. Suppressive effect of microRNA-143 in retinoblastoma. International journal of ophthalmology. 2016;9(11):1584-90.

38. Kumar N, Gangappa D, Gupta G, Karnati R. Chebulagic acid from Terminalia chebula causes G1 arrest, inhibits NFkappaB and induces apoptosis in retinoblastoma cells. BMC complementary and alternative medicine. 2014;14:319.

39. Zhao Y, Zhang S, Zhang Y. MicroRNA-320 inhibits cell proliferation, migration and invasion in retinoblastoma by targeting specificity protein 1. Molecular medicine reports. 2017;16(2):2191-8.
40. Fotinos A, Nagarajan N, Martins AS, Fritz DT, Gargett D, Lee AT, et al. Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells. Anticancer research. 2014;34(5):2095-104.

41. Sercu S, Zhang L, Merregaert J. The extracellular matrix protein 1: its molecular interaction and implication in tumor progression. Cancer investigation. 2008;26(4):375-84.

42. Wang Z, Zhou Q, Li A, Huang W, Cai Z, Chen W. Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer. OncoTargets and therapy. 2019;12:1423-32.

43. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Annals of surgery. 2005;242(3):353-61; discussion 61-3.

44. Lee KM, Nam K, Oh S, Lim J, Kim RK, Shim D, et al. ECM1 regulates tumor metastasis and CSC-like property through stabilization of beta-catenin. Oncogene. 2015;34(50):6055-65.

45. Chen H, Jia W, Li J. ECM1 promotes migration and invasion of hepatocellular carcinoma by inducing epithelial-mesenchymal transition. World journal of surgical oncology. 2016;14(1):195.
Figure legends

Figure1. The miR-486-3p level in normal and retinoblastoma (RB) tissues and cells were observed. A: The human tissue samples were taken from 45 patients with RB who were underwent eye enucleation, quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect miR-486-3p expressions in normal retinal tissues (normal group) and RB tumor tissues (RB group). B: The miR-486-3p expression in ARPE-19, Y79, SO-RB50 and WERI-Rb-1 cell lines were detected by qRT-PCR. 1A: **P<0.01 vs. normal; 1B: **P<0.01 vs. ARPE-19.

Figure2. The effects of miR-486-3p on cell proliferation and apoptosis were observed. A: Y79 and SO-RB50 were transfected with miR-486-3p mimic (mimic group) or mimic control (mimic control group), and a blank group was established, the miR-486-3p expression was detected by qRT-PCR. B: Cell viability of Y79 cells was determined by cell counting kit-8 kit (CCK-8). C: Cell viability of SO-RB50 cells was determined by CCK-8. D: Cloning ability of Y79 and SO-RB50 cells was determined by clone formation assay. E: The clones of RB cells were inhibited by miR-486-3p mimic. F: Apoptosis rates of RB cells were promoted by miR-486-3p mimic. G: Apoptosis of Y79 and SO-RB50 cells was determined by flow cytometry. **P<0.01 vs. Blank, ##P<0.01 vs. mimic control.

Figure3. Expressions of Bcl-2, Bax and cleaved caspase-3 (C caspase-3) in RB cells were observed. A: Expressions of Bcl-2, Bax and C caspase-3 in Y79 cells were detected by western blot. B: In Y79, miR-486-3p mimic decreased Bcl-2 level, and increased Bax and C caspase-3 levels. C: Expressions of Bcl-2, Bax and C caspase-3
in SO-RB50 cells were detected by western blot. D: In SO-RB50, miR-486-3p mimic decreased Bcl-2 level, and increased Bax and C caspase-3 levels. **P<0.01 vs. Blank, #P<0.01 vs. mimic control.

Figure 4. The effects of miR-486-3p on migration and invasion of RB cells were observed. A: Cell migration of Y79 and SO-RB50 was determined by scratch assay. B: In Y79 and SO-RB50, cell migration was inhibited by miR-486-3p mimic. C: In Y79 and SO-RB50, cell invasion was inhibited by miR-486-3p mimic. D: Cell invasion of Y79 and SO-RB50 was determined by transwell. **P<0.01 vs. Blank, #P<0.01 vs. mimic control.

Figure 5. The potential target of miR-486-3p was predicted and verified. A: Targetscan7.2 predicted that ECM1 was a potential target gene of miR-486-3p. B: Y79 and SO-RB50 were co-transfected with miR-486-3p mimic and ECM1-WT or ECM1-MUT, and the luciferase activities were measured by dual-luciferase reporter. **P<0.01 vs. Blank.

Figure 6. The role of miR-486-3p combined with ECM1 in RB cells was observed. A: Y79 was co-transfected with miR-486-3p mimic and ECM1 or their negative control (mimic control+NC group, mimic control+ ECM1 group, mimic + NC group, mimic + ECM1 group), the ECM1 protein level was detected by western blot. B: SO-RB50 was co-transfected with miR-486-3p mimic and ECM1 or their negative control (mimic control+NC group, mimic control+ ECM1 group, mimic + NC group, mimic + ECM1 group), the ECM1 protein level was detected by western blot. C: The miR-486-3p mimic decreased ECM1 level, while ECM1 reversed the effect of the
miR-486-3p mimic. D: Cell viability of Y79 and SO-RB50 was determined by CCK-8. E: Apoptosis of Y79 and SO-RB50 was determined by flow cytometry. F: In Y79 and SO-RB50, ECM1 inhibited apoptosis, and partially reversed the promoting effect of miR-486-3p on apoptosis. G: Cloning ability of Y79 and SO-RB50 cells was determined by clone formation assay. H: ECM1 increased cell cloning and partially reversed the inhibitory effect of miR-486-3p on cell cloning. **P<0.01 vs. mimic control+NC; ##P<0.01 vs. mimic control +ECM1; ^^^P<0.01 vs. mimic+NC.

Figure 7. The role of miR-486-3p combined with ECM1 in migration and invasion of RB cells was observed. A: Cell migration of Y79 and SO-RB50 was determined by scratch assay. B: In Y79 and SO-RB50, cell migration was promoted by ECM1, and ECM1 reversed the inhibitory effect of miR-486-3p on cell migration. C: In Y79 and SO-RB50, cell invasion was promoted by ECM1, and ECM1 reversed the inhibitory effect of miR-486-3p on cell invasion. D: Cell invasion of Y79 and SO-RB50 was determined by transwell. **P<0.01 vs. mimic control+NC; ##P<0.01 vs. mimic control +ECM1; ^^^P<0.01 vs. mimic+NC.
### Figure A

**Y79**

| Protein   | Blank | Mimic Control | Mimic |
|-----------|-------|---------------|-------|
| Bcl-2     | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) |
| Bax       | ![Image](image4.png) | ![Image](image5.png) | ![Image](image6.png) |
| C caspase-3 | ![Image](image7.png) | ![Image](image8.png) | ![Image](image9.png) |
| GAPDH     | ![Image](image10.png) | ![Image](image11.png) | ![Image](image12.png) |

**Relative protein/GAPDH expression level**

- **Bcl-2**
  - Blank: 1.00 ± 0.05
  - Mimic control: 0.80 ± 0.02
  - Mimic: 0.60 ± 0.01
- **Bax**
  - Blank: 1.00 ± 0.05
  - Mimic control: 0.60 ± 0.02
  - Mimic: 0.40 ± 0.01
- **C caspase-3**
  - Blank: 1.00 ± 0.05
  - Mimic control: 0.80 ± 0.02
  - Mimic: 0.60 ± 0.01

### Figure C

**SO-RB50**

| Protein   | Blank | Mimic Control | Mimic |
|-----------|-------|---------------|-------|
| Bcl-2     | ![Image](image13.png) | ![Image](image14.png) | ![Image](image15.png) |
| Bax       | ![Image](image16.png) | ![Image](image17.png) | ![Image](image18.png) |
| C caspase-3 | ![Image](image19.png) | ![Image](image20.png) | ![Image](image21.png) |
| GAPDH     | ![Image](image22.png) | ![Image](image23.png) | ![Image](image24.png) |

**Relative protein/GAPDH expression level**

- **Bcl-2**
  - Blank: 1.00 ± 0.05
  - Mimic control: 0.80 ± 0.02
  - Mimic: 0.60 ± 0.01
- **Bax**
  - Blank: 1.00 ± 0.05
  - Mimic control: 0.60 ± 0.02
  - Mimic: 0.40 ± 0.01
- **C caspase-3**
  - Blank: 1.00 ± 0.05
  - Mimic control: 0.80 ± 0.02
  - Mimic: 0.60 ± 0.01
A

Position 255-261 of ECM1 3' UTR

hsa-miR-486-3p

5'...CUGAGGCCACGGCCCCUGCCCC...3'

3' UAGGACAUGACUCGAAGGGGC

B

Y79

Relative luciferase activity

Blank  
Mimic

ECM1-WT  
ECM1-MUT

C

SO-RB50

Relative luciferase activity

Blank  
Mimic

ECM1-WT  
ECM1-MUT

**
| Name                              | 5'-3'                                      |
|----------------------------------|--------------------------------------------|
| miR-486-3p mimic                 | CGGGGCAGCUCAGUACAGGAU                      |
| miR-486-3p mimic control         | UCACAACCUCCUAGAAAGAUAGA                    |
| ECM1                             | Sence: CAAGATCTATGGGGACCACAGCCAGAGC       |
|                                  | Antisence: CAGGTACCGTCTCTCCTTGGGCTCAGAG   |
| ECM1 negative control            | AATTCACTCCAAAGTCTCTTTCC                   |
Table 2. The primers for qRT-PCR

| Name  | Forward: 5'-3'                      | Reverse: 5'-3'                      |
|-------|------------------------------------|-------------------------------------|
| miR-486-3p | GCCAGCTCAGTACAGGATAA A | CGGGGCAGUCAGUACAGGA U |
| U6     | CTCGCTTCGGCAGCACA               | AACGCTTCACGAATTTGCGT               |